Circulating Tumor Cells: From the Laboratory to the Cancer Clinic

Sawabata, Noriyoshi

doi:10.3390/cancers12103065

Cited by 10 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, unlike blood cells, the number of CTCs in blood is very small and they are difficult to detect. Therefore, various ingenuity has been made [15]. There are two CTC detection methods: use of surrogate markers and separation based on morphological features [9].…”

Section: Discussionmentioning

confidence: 99%

Verification of a new filter for extraction of circulating tumor cells by whole blood filtration

Morita

Sawabata

Tatsumi

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Since circulating tumor cells (CTCs) are precursors of metastatic lesions, extracting CTCs from whole blood is useful in obtaining information for cancer treatment. One of the CTC extraction methods is the size selection method; however, since the conventional methods are expensive and cumbersome, we developed an affordable and simple filter, whose usefulness is verified in this study. Methods: The new filter (hereafter, soft micropore filter [SMPF]) is made up of a polyethylene film with a thickness of 15 μm and conical pores having a diameter of 8–10 μm, which are opened uniformly (opening rate, 20%). This filter can filter whole blood by free-falling under gravity. The possibilities of the filter’s usage for model CTC extraction, immunostaining, short-term cell culture, and gene mutation detection in extracted model CTCs were verified. Results: S-MPF was able to extract model CTCs with an extraction rate of up to 15%. These model CTCs were detected by cytology, immunostaining, and culture by short-term incubation of filtered cells. Furthermore, genetic mutations were identified in the cultured cells. In addition, CTC extraction from the peripheral blood of patients with lung cancer was demonstrated by setting the volume of collected blood to 15 mL to prevent a low recovery rate. Conclusions: The S-MPF can be used to extract model CTCs quickly and easily. Moreover, cytological diagnosis, immunostaining, short-term culture, and gene mutation search are possible with this filter. Given its proven applicability in clinical samples, this sample can be used in clinical settings.

show abstract

Section: Discussionmentioning

confidence: 99%

Verification of a new filter for extraction of circulating tumor cells by whole blood filtration

Morita

Sawabata

Tatsumi

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are some technical issues to overcome to use CTCs isolated by a screening tool for early detection of solid cancer or its recurrence after treatment, including: The sample sources. Based on CTC source (peripheral blood, urine, saliva, or other biological fluids), the spatial clonal heterogeneity could lead to false-negative results by underestimating the disease burden due to the presence of remaining tumor cells in not accessible sites, which could be monitored with coupled imaging techniques, such as PET or MRI or circulating free DNA (cfDNA) by NGS., Several means to isolate and manipulate CTCs have recently emerged, ranging from using microfluidic to dielectrophoresis techniques [ 109 , 110 ], starting from different kinds of biological fluids [ 111 ] other than peripheral blood. For PC, there is an emerging interest for seminal plasma since the electrophoresis of seminal plasma cfDNA can discriminate between subjects carrying tumor or benign proliferation [ 111 ].…”

Section: The Role Of Ctcs In Precision Medicinementioning

confidence: 99%

The Role of Dielectrophoresis for Cancer Diagnosis and Prognosis

Russo

Musso

Romano

et al. 2021

Cancers

View full text Add to dashboard Cite

Liquid biopsy is emerging as a potential diagnostic tool for prostate cancer (PC) prognosis and diagnosis. Unfortunately, most circulating tumor cells (CTC) technologies, such as AdnaTest or Cellsearch®, critically rely on the epithelial cell adhesion molecule (EpCAM) marker, limiting the possibility of detecting cancer stem-like cells (CSCs) and mesenchymal-like cells (EMT-CTCs) that are present during PC progression. In this context, dielectrophoresis (DEP) is an epCAM independent, label-free enrichment system that separates rare cells simply on the basis of their specific electrical properties. As compared to other technologies, DEP may represent a superior technique in terms of running costs, cell yield and specificity. However, because of its higher complexity, it still requires further technical as well as clinical development. DEP can be improved by the use of microfluid, nanostructured materials and fluoro-imaging to increase its potential applications. In the context of cancer, the usefulness of DEP lies in its capacity to detect CTCs in the bloodstream in their epithelial, mesenchymal, or epithelial–mesenchymal phenotype forms, which should be taken into account when choosing CTC enrichment and analysis methods for PC prognosis and diagnosis.

show abstract

“…Based on the CTCs source (peripheral blood, urine, saliva, or other biological fluids), the spatial clonal heterogeneity could lead to false negative results, by underestimating the disease burden due to the presence of remaining tumor cells in not accessible sites, that could be monitored with coupled imaging techniques, such as PET or MRI or circulating free DNA (cfDNA) by NGS. Recently, several means to isolate and manipulate CTCs have emerged, ranging from using microfluidic to dielectrophoresis techniques 99,100 , starting from different kind of biological fluids 101 other than peripheral blood. For prostate cancer there is an emerging interest for seminal plasma, since the electrophoresis of seminal plasma cfDNA enabled the discrimination between subjects carrying tumor or benign proliferation 101 .…”

Section: The Role Of Ctcs In Precision Medicinementioning

confidence: 99%

Challenging the Current Paradigm of Liquid Biopsy Through Dielectrophoresis (DEP) In Prostate Cancer

Russo¹,

Musso²,

Romano³

et al. 2021

Preprint

View full text Add to dashboard Cite

Liquid biopsy via isolation of circulating tumour cells (CTCs) represents a promising diagnostic tool capable of supplementing state-of-the-art for prostate cancer (PC) prognosis. Unfortunately, most of CTC technologies, such as AdnaTest or Cellsearch, critically rely on the Epithelial-Cell-Adhesion-Molecule (EpCAM) marker, limiting the possibility of detecting stem-like cells (CSCs) and mesenchymal-like cells (EMT-CTCs) that are present during PC progression. In this tontext, dielectrophoresis (DEP) is an epCAM independent, label-free, enrichment system, separating rare cells simply on the basis of their specific electrical properties. As compared to other technollgies, DEP represents a superior technique in terms of running costs, cells yield and specificity, but due to its higher complexity, requires still further technical as well as clinical development. Interestingly, DEP can be improved by the use of microfluid, nanostructured materials and fluoroimaging in order to increase its potential applications. In the context of PC, the utility of DEP can be translated in its capacity to detect CTC in the bloodstream in their epithelial, mesenchymal, or epithelial-mesenchymal phenotypes, which should be taken into account when choosing CTC enrichment and analysis methods for PC prognosis and early diagnosis.

show abstract

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic

Abstract: Circulating tumor cells (CTCs) are cells that are separated from the primary tumor, move through the bloodstream, and spread from the original tumor to other sites, causing cancer metastasis [...]

Cited by 10 publications

References 15 publications

Verification of a new filter for extraction of circulating tumor cells by whole blood filtration

Verification of a new filter for extraction of circulating tumor cells by whole blood filtration

The Role of Dielectrophoresis for Cancer Diagnosis and Prognosis

Challenging the Current Paradigm of Liquid Biopsy Through Dielectrophoresis (DEP) In Prostate Cancer

Contact Info

Product

Resources

About